http://orcid.org/0000-0003-1630-1417
REFERENCES
- Fleischman, A. R., and L. K. Collogan. 2008. Research with children. In The oxford textbook of clinical research ethics, ed. Ezekiel J. Emanuel, Christine Grady, Robert A. Crouch, Reidar K. Lie, Franklin G. Miller, and David Wendler, 446–460. New York: Oxford University Press.
- Food and Drug Administration (FDA). 2019. Electronic Code of Federal Regulations. 21 CFR 50. https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/CFRsearch.cfm?CFRPart=50 (accessed January 14, 2020)
- Janofsky, J., and B. Starfield. 1981. Assessment of risk in research on children. The Journal of Pediatrics 98(5): 842–846. doi: 10.1016/S0022-3476(81)80865-7.
- Johnson, L. M., D. M. Duenas, and B. S. Wilfond. 2020. Ethical drug development for rare childhood diseases: When there are limited but promising data in adults, how to choose between safety or efficacy studies? The American Journal of Bioethics 20(4): 102–103.
- Lee, S. W., and J. C. Ginsberg. 2020. Balancing scientific progress with pediatric populations: No direct benefit now, but potential novel therapy in the future. The American Journal of Bioethics 20(4): 108–110.
- Matsler, J., and J. Young. 2020. When higher risk does not equal greater harm: Doing the most good in a limited pediatric study population. The American Journal of Bioethics 20(4):118–120.
- Nelson, R. M. 2020. The use of pediatric extrapolation to avoid unnecessary pediatric clinical trials. The American Journal of Bioethics 20(4): 48–50.
- Office for Human Research Protections, Secretary’s Advisory Committee on Human Research Protections (SACHRP). 2005. SACHRP Chair Letter to HHS Secretary Regarding Recommendations, Appendix B: Recommendations regarding risk in research involving children. https://www.hhs.gov/ohrp/sachrp-committee/recommendations/2005-july-28-letter-appendix-b/index.html (accessed January 14, 2020).
- Porter, K. M., A. Stevens, and B. S. Wilfond. 2020. Flexibility required: Balancing the interests of children and risk in drug development for rare pediatric conditions. The American Journal of Bioethics 20(4): 116–118.
- Shah, S., A. Whittle, B. Wilfond, G. Gensler, and D. Wendler. 2004. How do institutional review boards apply the federal risk and benefit standards for pediatric research? Jama 291(4):476–482. doi: 10.1001/jama.291.4.476.
- Sharma, A., and L. M. Johnson. 2020. Bringing known drugs to pediatric research – Safety, efficacy, and the ambiguous minor increase in minimal risk. The American Journal of Bioethics 20(4): 106–108.
- U.S. Department of Health and Human Services (DHHS). 2018. Electronic Code of Federal Regulations. 45 CFR 46. https://www.hhs.gov/ohrp/regulations-and-policy/regulations/revised-common-rule-regulatory-text/index.html (accessed January 14, 2020).
- Unguru, Y. 2020. Balancing risk and reward: Research with novel therapies for children with life-limiting illness. The American Journal of Bioethics 20(4): 104–105.
- Wilfond, B. S., D. M. Duenas, and L. M. Johnson. 2020. Greater than minimal risk, no direct benefit: Bridging drug trials and novel therapy in pediatric populations. The American Journal of Bioethics 20(4):102–103.